linomide linomide linomide (roquinimex) is a quinoline derivative immunostimulant which increases nk cell activity and macrophage cytotoxicity. it also inhibits angiogenesis and reduces the secretion of tnf alpha. linomideclinical dataatc codel03ax02 (who) pharmacokinetic dataelimination half-life26-42 hoursidentifiers iupac name 4-hydroxy-n,1-dimethyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide cas number84088-42-6 ypubchem cid54676478drugbankdb11366chemspider10619239 nunii372t2944c0keggd05756chebichebi:92056chemblchembl11672comptox dashboard (epa)dtxsid4045680 echa infocard100.163.758 chemical and physical dataformulac18h16n2o3molar mass308.337 g·mol−13d model (jsmol)interactive image smiles cn1c2=cc=cc=c2c(=c(c1=o)c(=o)n(c)c3=cc=cc=c3)o inchi inchi=1s/c18h16n2o3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21h,1-2h3 nkey:sgooqmripaltel-uhfffaoysa-n n ny (what is this?) (verify) linomide has been investigated as a treatment for some cancers (including as adjuvant therapy after bone marrow transplantation in acute leukemia) and autoimmune diseases, such as multiple sclerosis and recent-onset type i diabetes. several trials have been terminated due to serious cardiovascular toxicity. synthesis linomide synthesis: ethyl 2-(methylamino)benzoate is condensed with ethyl malonate. amine-ester interchange of that compound with n-methylaniline results in formation of the amide linomide.